

## WHO

Henao-Restrepo AM, Preziosi MP, Wood D, et al. [On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa](#). *Curr Opin Virol* 2016 May 12;17:138-144. [Epub ahead of print]

[Ebola Situation Report](#) (May 12, 2016)

[Liberia and Guinea discharge final Ebola patients in latest flare-up and begin 42 days of heightened surveillance](#) (May 2, 2016)

## Global Health Technologies Coalition

[Achieving a bold vision for global health: Policy solutions to advance global health R&D. 2016 Policy Report](#)

## National Academy of Medicine

[Vaccines: Ebola, SARS, MERS, Nipah, Zika virus, and beyond](#) (May 15-16, 2016). [Agenda](#)

## MEDICAL LITERATURE – REPORTS AND COMMENTARIES

Agnandji ST, Huttner A, Zinser ME, et al. [Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe](#). *New Engl J Med* 2016 Apr 28;374(17):1647-60.

Do TS, Lee YS. [Modeling the Spread of Ebola](#). *Osong Public Health Res Perspect* 2016 Feb;7(1):43-8.

Ewer K, Rampling T, Venkatraman N, et al. [A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA](#). *N Engl J Med* 2016 Apr 28;374(17):1635-46.

Fang LQ, Yang Y, Jiang JF, et al. [Transmission dynamics of Ebola virus disease and intervention effectiveness in Sierra Leone](#). *Proc Natl Acad Sci U S A*. 2016 Apr 19;113(16):4488-93.

Gittings K, Matson KL. [Establishing herd immunity against Ebola through vaccination](#). *Vaccine* 2016 Apr 25. pii: S0264-410X(16)30201-8.

Guo Z, Xiao D, Li D, et al. [Predicting and Evaluating the Epidemic Trend of Ebola Virus Disease in the 2014-2015 Outbreak and the Effects of Intervention Measures](#). *PLoS One* 2016 Apr 6;11(4):e0152438.

Henao-Restrepo AM, Preziosi MP, Wood D, et al. [On a path to accelerate access to Ebola vaccines: The WHO's research and development efforts during the 2014-2016 Ebola epidemic in West Africa](#). *Curr Opin Virol* 2016 May 12;17:138-144. [Epub ahead of print]

Huo X, Shi G, Li X, et al. [Knowledge and attitudes about Ebola vaccine among the general population in Sierra Leone](#). *Vaccine* 2016 Apr 4;34(15):1767-72.

Kieny MP, Longini IM, Henao-Restrepo AM, et al. [Changes in the primary outcome in Ebola vaccine trial--Authors' reply](#). *Lancet* 2016 Apr 9;387(10027):1509-10.

Krahling V, Becker D, Rohde C, et al. [Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus](#). Med Microbiol Immunol 2016 Apr;205(2):173-83.

Martins KA, Jahrling PB, Bavari S, et al. [Ebola Virus Disease candidate vaccines under evaluation in clinical trials](#). Expert Rev Vaccines 2016 May 10.

Murphy AA, Redwood AJ, Jarvis MA. [Self-disseminating vaccines for emerging infectious diseases](#). Expert Rev Vaccines 2016;15(1):31-9.

Pagliusi S, Ting CC, Khomvilai S, DCVMN Executive, Organising Committee Group. [Quality vaccines for all people: Report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05-07th October 2015, Bangkok, Thailand](#). Vaccine 2016 Mar 3.

Schmaljohn A, Lewis GK. [Cell-targeting antibodies in immunity to Ebola](#). Pathog Dis 2016 Jun;74(4):10.1093/femspd/ftw021. Epub 2016 Mar 21.

Spengler JR, Ervin ED, Towner JS, et al. [Perspectives on West Africa Ebola Virus Disease Outbreak, 2013-2016](#). Emerg Infect Dis 2016 Jun;22(6):956-963. Epub 2016 Jun 15.

Vu H, Shulenin S, Grolla A, et al. [Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans](#). Antiviral Res 2016 Feb;126:55-61.

Zhang Y, Feng S, Cowling BJ. [Changes in the primary outcome in Ebola vaccine trial](#). Lancet 2016 Apr 9;387(10027):1509.

## **SCIENCE NEWS**

[Liberia: PREVAIL wants health workers take Ebola vaccine](#) (StarAfrica, May 4, 2016)

[Security spending must cover disease outbreaks](#) (Nature, May 3, 2016)

[Ebola vaccine: Promising phase I trials](#) (EurekaAlert!, May 3, 2016)

[Ebola virus does a total shutdown to hide before a fresh strike](#) (New Scientist, Apr. 29, 2016)

[Immunisation for an economic foundation](#) (CPI Financial, Apr. 27, 2016)

[How the Ebola vaccine broke new ground](#) (Politico, Apr. 27, 2016)

[Vaccines community aims for proactive approach to combat frequent, rapid outbreaks](#) (FiercePharma, Apr. 26, 2016)

[Experimental Ebola vaccines need testing](#) (Financial Times, Apr. 25, 2016)

[NewLink Genetics awarded \\$21.6 million contract option for Ebola vaccine development](#) (Reuters, Apr. 25, 2016)

[Experimental Ebola vaccines need testing](#) (Financial Times, Apr. 25, 2016)

[Feds re-up with support for development of NewLink's Ebola vaccine](#) (Seeking Alpha, Apr. 25 2016)

[Combo of J&J Ebola vaccine, Nordic Bavarian booster yields 100% success in small-scale tests](#) (BioPharmaDive, Apr. 21, 2016)

[Trial suggests potential for sequential use of 2 Ebola vaccines](#) (CIDRAP News, Apr. 20, 2016)

[Ebola vaccine results lift clinical spirits](#) (Times of Malta, Apr. 19, 2016)

[DOD awards NewLink Genetics \\$2.8M to develop filovirus jab](#) (FiercePharma, Apr. 18, 2016)